article thumbnail

A realistic view of healthcare in 2022

World of DTC Marketing

1ne: The value proposition of prescription drugs still outweighs potential side effects – Wegovy’s demand quickly exceeded supply after the FDA approved once-weekly semaglutide injections. People don’t want to lose weight through diet and exercise if they can lose it through a prescription drug.

article thumbnail

Filling the gap—and the prescription—with GoodRx

Fierce Pharma

Filling the gap—and the prescription—with GoodRx. Thu, 11/10/2022 - 18:49.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Does anyone really believe pharma cares what people think?

World of DTC Marketing

The pharma industry’s reputation continues to slip from a pandemic halo-high of 62% in February 2021 to now when fewer than half, just 47%, of people have a favorable view of the industry, according to the Harris Poll’s latest survey. Source: Endpoints News ) Does anyone believe that pharma cares?

Pharma 183
article thumbnail

The Top-Performing OTC and Rx Pharma Ads Generated 56 Million Searches in 2022

PM360

Over-the-Counter (OTC) and Prescription (Rx) brands have invested over $3 billion in linear TV advertising during the first half of 2022, with no signs of letting up. Pharma ads generate strong consumer engagement and drive TV viewers to seek additional information online via a search engine such as Google. Impressions.

Pharma 98
article thumbnail

Pharma Injecting Life into Digital Health Amidst Funding Downturn

MedCity News

The consensus is 2022 was a challenging year for digital health companies. billion in 2022 — down 56% from $40.2 billion in 2022 — down 56% from $40.2 Rather, 2022 represents an overdue correction in the midst of global economic uncertainty after a period of overexuberance and lofty expectations in digital health.

Pharma 103
article thumbnail

Marketing to Type 2 Diabetes Patients: How Pharma Can Increase Treatment Awareness, Improve Outcomes

PM360

However, despite being one of the biggest markets in pharma, diabetes drugmakers have a hard time standing out in the crowded field, and many patients still aren’t confident in their ability to manage their disease. Patients are willing to explore new prescription therapies as well, but most are unaware of their available options.

article thumbnail

Pharma says VPAS clawback jeopardises UK sector

pharmaphorum

A pharma industry organisation has warned that record levels of revenue clawback from the UK government is threatening “footprint, R&D and manufacturing investments” in the country. billion in 2022, and there has been speculation that the return rate could rise into the 30%-plus range in future. billion in 2021 to £1.8

Pharma 70